Back to results
US 5,443,505 AGranted
Biocompatible ocular implants
AssigneeOculex Pharmaceuticals, Inc.
InventorsVernon G. Wong, Frank Kochinke
Life of this patent
Estimating the term…
Abstract
Implants comprising active agents are employed for introduction into a suprachoroidal space or an avascular region of an eye for therapeutic purposes. The administration of drags is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.
Claims19
A method for treating an eye condition which comprises:
- preparing an implant by combining a physiologically active therapeutic agent and a permeability enhancing agent encapsulated in a pharmacologically acceptable biocompatible polymer;
- and
- introducing said implant extrinsic to the vitreous and incapable of migration from an implantation site, wherein said site is characterized by being avascular, permitting diffusion of a physiologically active agent from said implant into the vitreous, and in proximity to said eye condition,
- wherein said therapeutic agent is maintained at an effective dosage for said eye condition at the site of said eye condition for an extended period of time.
1 more element
A method for treating an eye condition which comprises:
- preparing an implant by combining a physiologically active therapeutic agent and a permeability enhancing agent encapsulated in a pharmacologically acceptable biocompatible polymer;
- and
- introducing into the avascular pars plana of an eye said implant incapable of migration from said pars plana, wherein one implantation site is characterized by permitting diffusion of a physiologically active agent from said implant into the vitreous, and in proximity to said eye condition,
- wherein said agent is maintained at an effective dosage for said eye condition at the site of said eye condition for an extended period of time.
1 more element
A method for treating choroidal tumors of an eye which comprises:
- preparing an implant by combining an antitumor agent and a permeability enhancing agent encapsulated in a pharmacologically acceptable biocompatible polymer;
- and
- introducing into an avascular region of a suprachoroidal space of said eye said implant incapable of migration from said space, wherein said implant provides an effective dosage of said antitumor agent over an extended period of time.
Dependencies are inferred from the claim text.